The FDA will decide by Nov. 9 on the supplemental new drug application for Bristol-Myers Squibb's Sprycel, or dasatinib, as a treatment for pediatric patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia to enhance the powder form of an oral suspension formula.
FDA grants priority review of supplemental NDA for leukemia drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.